TGTX (STOCKS)
TG Therapeutics, Inc.
$28.820000
-0.320000 (-1.10%)
Prev close: $29.140000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Michael Sean Weiss
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $4,621.44M
- Employees
- 352
- P/E (TTM)
- 10.49
- P/B (TTM)
- 7.45
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
9
Buy
2
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$0.16 | $0.22 | -0.0644 | -28.70% |
|
Jun 2025 (Q2)
|
$0.17 | $0.22 | -0.0515 | -23.25% |
|
Mar 2025 (Q1)
|
$0.03 | $0.19 | -0.1555 | -83.83% |
|
Dec 2024 (Q4)
|
$0.15 | $0.08 | +0.0653 | +77.10% |
Financial Statements
| Revenues | $531.90M |
| Benefits Costs and Expenses | $444.15M |
| Cost Of Revenue | $77.97M |
| Costs And Expenses | $429.12M |
| Gross Profit | $453.93M |
| Nonoperating Income/Loss | -$15.03M |
| Operating Expenses | $351.15M |
| Selling, General, and Administrative Expenses | $208.25M |
| Research and Development | $142.90M |
| Operating Income/Loss | $102.78M |
| Income/Loss From Continuing Operations After Tax | $447.47M |
| Income/Loss From Continuing Operations Before Tax | $87.75M |
| Income Tax Expense/Benefit | -$359.72M |
| Net Income/Loss | $447.47M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $447.47M |
| Net Income/Loss Available To Common Stockholders, Basic | $447.47M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $3.07 |
| Diluted Earnings Per Share | $2.77 |
| Basic Average Shares | 438,809,598 |
| Diluted Average Shares | 162,071,497 |
| Assets | $1.03B |
| Current Assets | $599.77M |
| Cash | $178.30M |
| Inventory | $146.95M |
| Other Current Assets | $274.51M |
| Noncurrent Assets | $425.26M |
| Liabilities | $417.81M |
| Current Liabilities | $156.81M |
| Noncurrent Liabilities | $261.00M |
| Equity | $607.22M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $607.22M |
| Liabilities And Equity | $1.03B |
| Net Cash Flow From Operating Activities | -$70.07M |
| Net Cash Flow From Operating Activities, Continuing | -$70.07M |
| Net Cash Flow From Investing Activities | $45.23M |
| Net Cash Flow From Investing Activities, Continuing | $45.23M |
| Net Cash Flow From Financing Activities | -$96.86M |
| Net Cash Flow From Financing Activities, Continuing | -$96.86M |
| Net Cash Flow | -$121.71M |
| Net Cash Flow, Continuing | -$121.71M |
| Comprehensive Income/Loss | $447.47M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $447.47M |
| Other Comprehensive Income/Loss | $0.00 |